Navigation Links
OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
Date:6/9/2008

VANCOUVER, June 9 /PRNewswire/ - OncoGenex Technologies Inc. will present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference on June 11 at 3 p.m. ET at the New York Palace Hotel. OncoGenex' President and Chief Executive Officer, Scott Cormack, will provide a corporate overview at the conference, including an overview of the Company's most recent data presentations from the American Society of Clinical Oncology (ASCO) 2008 and the American Society of Clinical Oncology (ASCO) Genitourinary 2008 cancer conferences.

About OncoGenex

OncoGenex is a private biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. The company's three product candidates are designed to inhibit the production of specific proteins associated with treatment resistance and which are over-produced in response to a variety of cancer treatments. OGX-011 is completing evaluation in five Phase 2 clinical studies in prostate, lung, and breast cancers. OGX-427 has begun evaluation in Phase 1 clinical studies, while the third product candidate, OGX-225, has completed preclinical pharmacology studies. More information is available at http://www.oncogenex.ca.

Definitive Agreement to Merge

On May 28, 2008, Sonus Pharmaceuticals, Inc. (NASDAQ: SNUS) and OncoGenex Technologies Inc., jointly announced the signing of a definitive agreement to merge the two companies. The proposed transaction is subject to the approval of Sonus' and OncoGenex' shareholders and in the case of OncoGenex, court approval under the arrangement provisions of the Canada Business Corporations Act.

<
'/>"/>
SOURCE OncoGenex Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
2. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
3. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
4. Gen-Probe to Webcast Presentation at Seventh Annual Needham Biotechnology and Medical Technology Conference
5. Inverness Medical Innovations to Present at 7th Annual Needham & Company, LLC Biotechnology & Medical Technology Conference on June 12, 2008
6. InterMune to Present at Goldman Sachs Healthcare and Needham & Co. Biotechnology and Medical Technology Conferences
7. Amylin Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference
8. Hologic to Present at the Needham Seventh Annual Biotechnology and Medical Technology Conference
9. Telik Announces Presentation and Webcast at Needham Biotechnology Conference
10. PAREXEL International to Present at Goldman Sachs 29th Annual Global Healthcare Conference
11. NxStage Medical to Present at William Blair Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... The November 2014 issue of BioTechniques ... access journal featuring the following articles:, , ... photoresponsiveness in the retina , DNA from ... using chromogenic substrates in zebrafish , Re-use ... electrophoresis , Nuclear LC3-positive puncta in stressed ...
(Date:11/21/2014)... 2014 Polaris Group announced today that ... Phase 1 trial of ADI-PEG 20 in combination ... malignant pleural mesothelioma (MPM) and non-squamous non-small cell ... on ADI-PEG 20, both as monotherapy and in ... several other indications, including breast cancer, melanomas, ovarian ...
(Date:11/18/2014)... November 17, 2014 RPS Diagnostics ... tests – today announces its third annual partnership ... (CDC) Get Smart About Antibiotics Week from November ... a national campaign designed to highlight the coordinated ... and non-profit and for-profit partners to provide education ...
(Date:11/18/2014)... American Process Inc. (Atlanta, GA) ... partnership with researchers at Georgia Institute of Technology, ... the USDA’s Forest Products Laboratory to develop ultra-strong, ... is a rapidly emerging high performance nanomaterial extracted ... to replace heavy steel structures within cars, such ...
Breaking Biology Technology:BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 2American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 3
... clinics, fits dozens ... of ... Touch,Bionics, developer of the world,s first commercially available bionic hand,today announced ... U.S. operations out of Boston, MA, this announcement,follows the company,s opening ...
... (OTC,Bulletin Board: RGBL) announced today that the company is ... treatment plant and discussed,numerous projected growth areas for the ... Schedule, RG Global,s Catalyx Fluid Solutions (CFS) expects ... first plant employing the,Catalyx Fluid Solutions ion exchange technology ...
... -, DALLAS, Jan. 29 ACCESS PHARMACEUTICALS, ... has executed agreements,for $2.7 million in new equity. ... accredited investors to purchase an aggregate of,$2.7 million ... Convertible,Preferred Stock. This equity is in addition to ...
Cached Biology Technology:Touch Bionics expands U.S. presence to meet demand for i-LIMB Hand 2Touch Bionics expands U.S. presence to meet demand for i-LIMB Hand 3Touch Bionics expands U.S. presence to meet demand for i-LIMB Hand 4RG Global Corporate Update: First Coal Bed Methane Water Treatment Plant Near Completion; Expanding Water Treatment Applications 2RG Global Corporate Update: First Coal Bed Methane Water Treatment Plant Near Completion; Expanding Water Treatment Applications 3Access Pharmaceuticals Announces $2.7 Million New Equity 2Access Pharmaceuticals Announces $2.7 Million New Equity 3
(Date:11/3/2014)... ANGELES , Nov. 3, 2014  NeuroSigma ... -based life sciences company focused on commercialization ... system for the treatment of neurological and ... of Industrial Property has issued a Notice of ... patent application is co-owned by NeuroSigma and the ...
(Date:11/2/2014)... month,s issue of Physics World , James Dacey ... "valley of death" to take their innovations from the ... the gruelling challenge facing all start-up companies as they ... physicists because of two main factors: physics-based inventions are ... often turn out to be a lot more complicated ...
(Date:11/2/2014)... a child, it was fascinating to put a flashlight ... through the hand. Washington University in St. Louis engineers ... the body,s tissues to improve imaging of cancerous tissues ... PhD, the Gene K. Beare Distinguished Professor of Biomedical ... is applying a novel time-reversal technology that allows researchers ...
Breaking Biology News(10 mins):NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3The 'valley of death' facing physics start-ups 2Improving imaging of cancerous tissues by reversing time 2
... tidal energy sufficient to power about half of Scotland could ... north coast of the country, engineers say. Researchers ... tidal power could be generated by turbines placed in the ... gigawatts (GW) could be available. The in-depth assessment by ...
... unusually strong El Ninos, such as the 1983 heatwave ... are likely to double in number as our planet ... the ARC Centre of Excellence for Climate System Science ... CSIRO, published their findings in the journal Nature ...
... in parts of Africa, Asia and South America contributes to ... world,s poor. The parasitic worm lives in the soil and ... blood, the worms cause anemia and, in children, stunted growth ... of Medicine in St. Louis have decoded the genome of ...
Cached Biology News:Island channel could power about half of Scotland, studies show 2Get used to heat waves: Extreme El Nino events to double 2Decoded: DNA of blood-sucking worm that infects world's poor 2
... Metalloproteinase-2, Hinge Region By immunoblotting the antibody ... It reacts with free MMP-2 or MMP-2 ... buffered aqueous glycerol solution Solution in ... containing 50% glycerol and 15 mM sodium ...
... This CLS number is ... created to easily match ... showing no availability yet, ... old Sigma-Aldrich number (Z71,381-3) ...
... is a new product number, ... product number. If showing no ... the old Sigma-Aldrich number (Z37,208-0) ... assistance. Mfr Desig: Corning ...
... Description: 100 g ... 70 kDa YAP from Human/mouse/rat samples. ... Research Focus: ... -20C Shipping ...
Biology Products: